O(6)-methylguanine DNA-methyltransferase (MGMT) in glioblastoma: Analysis on first and following surgeries.

Neuro-oncology: a selected review of ASCO 2011 abstracts

“…Five articles were presented in relation to molecular correlatives, four concerning GBM and one AG [60][61][62][63][64]. In an ana lysis of the German Glioma Network database, 233 elderly patients (median age: 74 years) underwent MGMT promoter methylation determination by two methods: DNA pyrosequencing and methylation-specific polymerase chain reaction (MSP-PCR) [61].…”

“…The combination was most predictive and outcome of patients with low IHC expression was a function of promoter methylation status. A small study of 15 patients with paired tumor samples obtained at initial surgery and at time of recurrence analyzed for MGMT methylation status demonstrated concordance for the majority of patients (>85%) [64]. In an ana lysis of the RTOG 0525 trial, four molecular biomarkers were defined in 82% of all submitted tumors: MSP-PCR, glioma CpG island methylation phenotype, a microarray mRNA-based panel of 19 genes and IDH1/2 mutational status [60].…”